Drugs of interest to pathologists
Drugs related to surgical pathology
Vandetanib

Author: Him G. Kwee, M.D. (see Authors page)

Revised: 11 December 2017, last major update December 2011

Copyright: (c) 2002-2017, PathologyOutlines.com, Inc.

PubMed Search: Vandetanib "loattrfree full text"[sb] review [ptyp]

Cite this page: Kwee, H.G. Vandetanib. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/drugsvandetanib.html. Accessed December 11th, 2018.
Definition / general
  • A multikinase inhibitor
Trade name
  • Initially called Zactima by AstraZeneca but changed to Caprelsa® in August 2011 to avoid confusion with other drugs
Clinical information
Uses by pathologists
  • Vandetanib inhibits VEGFR-2 (vascular endothelial growth factor receptor), EGFR and RET-tyrosine kinase activity (RET means rearranged during transfection proto-oncogene)
  • 25% of hereditary MCT cases are associated with RET mutations but the efficacy of vandetanib is independent of the RET mutation status of MCT (cancer.gov: FDA Approves New Treatment for Medullary Thyroid Cancer [Accessed 11 December 2017])
  • Vandetanib should not be used if there is hypocalcemia, hypokalemia, hypomagnesemia or in long QT interval syndrome, since it can cause life threatening cardiac arrhythmias
  • Other side effects include:
    • Hypothyroidism
    • Reversible posterior leukoencephalopathy syndrome
    • Acne, photosensitivity and Stevens-Johnson syndrome
    • Interstitial lung disease
    • Diarrhea with electrolyte imbalance (AstraZeneca news bulletin August 1, 2011)